URL: https://fortune.com/well/2023/12/01/flu-covid-rsv-syndemic-tripledemic-winter-2023-respiratory-virus/
TITLE: Forget the â€˜tripledemic.â€™ The U.S. is headed for a â€˜syndemicâ€™ this 2023 winterâ€”and experts warn weâ€™re not prepared | Fortune Well
Forget the â€˜tripledemic.â€™ The U.S. is headed for a â€˜syndemicâ€™ this winterâ€”and experts warn weâ€™re not prepared COVID will likely reach levels in December not yet seen this year, combining with surges of flu, RSV, and other pathogens for a winter not so different from last yearâ€™s  â€œtripledemic,â€  experts say. Raj Rajnarayanan, assistant dean of research and associate professor at the New York Institute of Technology campus in Jonesboro, Ark., told  Fortune  that the U.S. is a â€œsitting duckâ€ in the face of a â€œsyndemicâ€ winter.Â  Itâ€™s a term he prefers to â€œtripledemic,â€ as it acknowledges the impact of more than three pathogens on the healthcare system, and the need for policies to address the phenomenon, in addition to medical interventions. â€œStrained hospital capacities, workforce exhaustion, burnout, a lack of effective therapeutic tools, poor communication, a lack of compliance [with COVID precautions], a lack of continuity planning, and the pervasive influence of social determinants of healthâ€ only make the nationâ€™s delicate health infrastructure more fragile, he said. COVID  wastewater levels are â€œhighâ€  and again headed upwards, on track to surpass their 2023 peak, which occurred in September, according to  wastewater data  posted by the U.S. Centers for Disease Control and Prevention. COVID hospitalizations are  up 10% week over week , according to the most recent data made available. And deaths, while not rising,  are not receding , either. Jay Weilandâ€”a top COVID forecaster cited by leading public health experts like Dr. Eric Topolâ€”told  Fortune  he has â€œlittle doubtâ€ that this winterâ€™s COVID wave will be the highest the country has seen since last winter, when Omicron spawn  XBB.1.5, or â€œKraken,â€  sent cases rocketing skyward yet again. Thereâ€™s a â€œreasonable chanceâ€ it surpasses last yearâ€™s wave, he addedâ€”but little chance it competes with the initial Omicron peak of the 2021â€“22 winter, when U.S. infections hit an all-time high. ğŸ”¹ï¸Preliminary winter forecast is out.  As JN.1 Pirola grows, it is forecast to push numbers up quickly in the coming weeks. There is a decent amount of uncertainty on how far JN.1 will penetrate our population's resistances, so a reasonable range for the peak is provided.  pic.twitter.com/XnPrza3p36 Meanwhile,  U.S. rates of hospitalization  from RSV and flu are also on the rise, and outpatient visits for respiratory illnesses are abnormally high,  according to CDC data . â€œLast year really showed what happens when we go a few years without seeing our normal viral trends,â€ Dr. Karen Acker, pediatric infectious diseases specialist at New Yorkâ€“Presbyterian Komansky Childrenâ€™s Hospital, told  Fortune  on Friday. Â  Itâ€™s a nod to the â€œimmunity debtâ€ theory, according to which infections from other pathogens spike after pandemic precautions are abandoned. Some blame the potential phenomenon for last yearâ€™s relatively severe winter respiratory disease season, which challenged hospital capacity in many locations. â€œIt may take some time for viral levels and the immunity dynamic to level out,â€ she added. â€œThis may be another bad year.â€ Flu surging, RSV â€˜near peakâ€™ But not all experts agree. Itâ€™s â€œpremature to say itâ€™s going to be a bad year here,â€ Dr. Michael Osterholmâ€”directorÂ of the University of Minnesotaâ€™s Center for Infectious Disease Research and Policy (CIDRAP)â€”recently told  Fortune.  While pathogens like flu and RSV peaked earlier than usual during last yearâ€™s so called â€œtripledemic,â€ the severity of the season â€œwasnâ€™t beyond usual.â€ Whatâ€™s more, low hospital bed capacity and staff levels were under-appreciated factors that contributed to the crisis, making it look worse than it was, he said. Encouragingly, while  U.S. rates of hospitalization  from COVID, RSV, and flu combined are on the rise, they remain below levels seen this time of year during the past two years. Still, theyâ€™re significantly higher than those seen in the two winters prior to the COVID-19 pandemic. RSV hospitalizations are the  highest theyâ€™ve been since 2020 , with the exception of last winter. And flu hospitalizations are the  highest theyâ€™ve been  at this time of year since 2017, when they were identicalâ€”also with the exception of last year. CDC Director Dr. Mandy Cohen on Thursday said U.S. flu season, while so far typical, is â€œaccelerating fast,â€ and that RSV levels are â€œnear peak,â€  in testimony before  the House Energy and Commerce Subcommittee on Oversight and Investigations. Multiple experts told  Fortune  that this winterâ€™s respiratory season should more closely resemble pre-pandemic years than last yearâ€™s, though it may take several years for typical seasonal viral patterns to reestablish. It may take a year or two before winter viral seasons return to normal, Osterholm recently told  Fortune.  Amesh Adalja, an infectious disease specialist and senior scholar at the Johns Hopkins Center for Health Security, told  Fortune  he expects a more standard season this year, â€œwith the exception that COVID-19 will remain a major force that impacts hospitalizations and death numbers.â€ Adalja expects the usual mix of COVID, flu, rhinovirus, metapneumovirus, RSV, adenovirus, and seasonal coronavirus, with most of the latter presenting as common colds. Itâ€™s possible, but uncertain, that the U.S. sees a surge in cases of  mycoplasma pneumoniae,  an atypical bacteria that can cause lung infection, experts say. Such a surge is  reportedly occurring in China  among youth, in addition to the Netherlands, Denmark, France, and  Ireland . Dr. Stuart Ray, vice chair of medicine for data integrity and analytics at Johns Hopkinsâ€™ Department of Medicine, doesnâ€™t have â€œstrong sense that this will be a particularly badâ€ respiratory season, he told  Fortune . â€œBut itâ€™s awfully hard to predict the future when it comes to respiratory pathogens, as weâ€™ve learned in recent years.â€ A recent U.K. case of a  strain of swine flu new to humans  â€œillustrates the uncertainties we always face on this topic,â€ Ray said. Officials with the World Health Organization on Friday said the sickened individual, who has recovered, lives close to pigs but had no contact with them, and that â€œlimited human-to-human transmission may have played a role,â€ though there is â€œno definitive evidence.â€ While Ray doesnâ€™t see the particular strain of swine flu posing a larger threat to humans this winter, â€œsomething like that is always looming as a possibility,â€ he said. COVID a continued wild card Of the three main winter respiratory pathogensâ€”COVID, flu, and RSVâ€”COVID remains the greatest threat this season, Cohen told Congress on Thursday. Itâ€™s â€œstill the respiratory virus putting the most number of folks in the hospital and taking lives,â€ she said. Experts are eyeing variant â€œPirola,â€ BA.2.86, and its descendants, like JN.1, in particular, saying their fast rate of spread could heightened an anticipated winter surge. Already, BA.2.86 and its descendants are thought to be behind  around 9% of COVID cases  in the U.S.â€”ranking third in the race for viral supremacy and lagging â€œEris,â€ EG.5, by only a few percentage points, according to CDC data released this past week. The BA.2.86 viral family also represents about 9% of sequences reported globally over the past month, with levels doubling each week for the past four weeks, according to a recent report from the World Health Organization. Last week it upgraded BA.2.86 and descendants to a  variant of interest  of global proportionsâ€”second only to the category of variant of concern. And the CDC  released a statement on the variant , saying it expects BA.2.86 and descendants to continue to grow in the U.S., and singling out JN.1 as a variant with particular potential to take off. While BA.2.86 and descendants arenâ€™t thought to cause more severe disease than other Omicron variants, according to the WHO, a greater-than-expected surge in cases would still pressure an already fragile U.S. health care system, experts say. â€˜Immunity debtâ€™ one of several theories While some experts point to the immunity debt theory as the driver behind wonky post-pandemic viral seasons, some experts say other theories should be considered. Among them: that COVID suppresses the immune systemâ€”at least temporarily, and at least in someâ€”making them more susceptible to other infections.Â  Another: that being infected with both COVID and another pathogen at the same time makes the other pathogen, like RSV, more severe. One additional: viral interference, in which competitive viruses like COVID â€œcancel outâ€ other viruses for a period of time. Such a phenomenon appears to have happened during the H1N1 bird flu pandemic of 2009, during which other strains of flu and RSV â€œdisappearedâ€ for a time, as Osterholm points out. Rajnarayanan points to a  recent article in the  British Medical Journal ,  the findings of which suggest that COVID contributed to last yearâ€™s surge of RSV cases â€œthrough the large buildup of COVID-19 infected children and the potential long-term adverse effects of COVID-19 on the immune and respiratory system.â€ â€œImmunity debt is one hypothesis,â€ Ryan Gregory, a biology professor at the University of Guelph in Ontario, Canada, told  Fortune.  But â€œthe consequences of getting the answer wrong requires us to test all available explanations and not to be content with making assumptions because an explanation sounds plausible.â€ Regardless of how we got here, increased exposure to viruses after a period of decreased exposureâ€”to pay the so-called immunity debtâ€”isnâ€™t helping anyone, Gregory contends. â€œThere is no circumstance in which more viruses circulating is a good thing,â€ he said. Â© 2023 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our  Terms of Use  and  Privacy Policy  |  CA Notice at Collection and Privacy Notice Â |  Do Not Sell/Share My Personal Information Â |  Ad ChoicesÂ  
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice. 
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.  Terms & Conditions . Powered and implemented by  Interactive Data Managed Solutions .